Prognostic Value of Leucocyte Telomere Length in Acute Myocardial Infarction

Introduction: Leucocyte telomere length (LTL) has been described as a marker of biological age, endothelial dysfunction and atherosclerosis. The association between LTL and clinical characteristics of Asian patients, and their outcomes following acute myocardial infarction (AMI) have been inconclusive. Objective: To investigate the relationship between LTL and developing AMI, the association of LTL with inpatient and 30-day mortality, and the comparison to LTL with established AMI risk scores in predicting these outcomes. Methodology: 100 patients aged 30-70 years admitted with an AMI to a tertiary referral center between May-Oct 2017 were enrolled; these were matched with 100 non-AMI ('healthy') controls for gender and age (+/- 1 year). Clinical data was obtained prospectively; inpatient and 30-day outcomes documented. LTL was reflected by a well described variable called a tis ratio (TSR). The TSR was measured at enrolment using a quantitative PCR-based methods (qPCR) and results blinded to the clinician

The Association Between N-Terminal B-Type Natriuretic Peptide and One Year Clinical Outcome in Patients with Acute Myocardial Infarction : A Multicenter Study

Background: NT-proBNP is a useful biomarker in the management of heart failure. However, there is conflicting evidence for the prognostic value of NT-ProBNP in acute myocardial infarction (AMI). Objectives: (1) To explore the association between NT-proBNP and 1-year cardiac related mortality in AMI patients. (2) To explore the association between NT-proBNP and 1-year risk of sudden cardiac death or ventricular arrhythmia, readmission for heart failure, readmission for acute coronary syndrome (ACS) and stroke. Methods: We conducted a multicenter, prospective observational study recruiting patients presenting with AMI between 1-August2016 to 31-January-2017, involving 1 cardiology referral center and 4 non-cardiology hospitals. NT-proBNP levels (Alere Triage®, US) were measured within 24 hours of AMI diagnosis. Patients were followed-up for 1 year